Accurate delivery of drugs at the second layer of the skin –i.e. dermis– is critical for achieving predictable skin therapies. Existing intradermal injection devices lack accuracy, are wasteful, but mainly, are time-consuming in use. As the global demand for efficient and safe delivery methods of intradermal drugs increases, it is evident that the expansion of the skin injectable therapy market critically hinges on the development of an injection device characterized by unprecedented efficiency. Using previously acquired StarTT funding, the MIDEQ injection device demonstrated unprecedented technical efficiency and versatility. The technical Proof of Concept (tPoC) not only resulted in a broad patent filing but allowed for the identification of additional intellectual property. With this StepStone application, we seek to further mature MIDEQ’s technology, by developing an industrial PoC and performing a preclinica validation. Furthermore, the commercial strategy including the go-to-market strategy and business plan will be further developed and required spin-off funding targeted.